RXi's subretinal fibrosis therapy well tolerated in Phase I/II

RXi Pharmaceuticals Corp. (NASDAQ:RXII) said RXI-109 was well tolerated with no treatment-related adverse events or dose-limiting toxicities (DLTs) reported in the Phase I/II RXI-109-1501 trial in nine patients with advanced neovascular age-related macular degeneration (AMD) and accompanying subretinal fibrosis.

Patients in the open-label, U.S. trial received four intravitreal injections of RXI-109 into one eye only at monthly intervals, followed by an observation period of four months...